Monday, September 17, 2012
In the News: The POWER of HERCULES
STAR and ASTRAL ( largest to date) have shown no significant benefit in interventional interventions for atherosclerotic renal artery stenosis(ARAS).
CORAL is still underway, here comes HERCULES. This is a large prospective multi-center single arm study of patients with significant RAS and uncontrolled HTN. This is in contrast to prior trails that had less sicker patients. Most were at least on 2 agents and 75% on ACEI or ARBS. The procedure related complications were only 1.5% compared to prior studies suggesting as high as 17%. The results suggested drop in SBP significantly at 9 months, low in stent restenosis rate and complication rates.
Regardless- check out the full trial at Catheterization and cardiovascular interventions.
- ► 2019 (42)
- ► 2018 (57)
- ► 2017 (52)
- ► 2016 (45)
- ► 2015 (63)
- ► 2014 (95)
- ► 2013 (133)
- eAJKD: smart allocation or bias?
- Clinical Case 62: Answers and Summary
- Want to be an attending physician on the ward - or...
- CJASN eJC: September discussion
- eAJKD updates: Medicine 2.0 coverage
- In the News: The POWER of HERCULES
- Nephrotic Syndrome: Pathophysiology update
- In the News: Kidney Transplant Chain- 1 year follo...
- Topic Discussion: Music therapy and kidney transpl...
- CLINICAL CASE 61: Answers and Summary
- Publication trends by speciality among Internal Me...
- NEPHSAP review: Glomerular Disease: Hematuria Risk...
- Hypercalcemia and hypokalemia- is there a link?
- NEPHRONPOWER 1000th post: A tribute to a Nate Hellman
- Special: Top 10 posts of all time on Nephronpower
- ▼ September (15)
- ► 2011 (370)
- ► 2010 (461)